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OXALIPLATIN FOR THE TREATMENT OF CISPLATIN-RESISTANT 
CANCER: A SYSTEMATIC REVIEW 
 
Abstract 
 
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We 
undertook a systematic review of the literature to identify, describe and critique the 
clinical and pre-clinical evidence for the use of oxaliplatin in patients with “cisplatin-
resistant” cancer. We identified 25 pre-clinical cell models of platinum resistance and 
24 clinical trials reporting oxaliplatin based salvage therapy for cisplatin-resistant 
cancer. The pre-clinical data suggests that there is cross-resistance between cisplatin 
and oxaliplatin in low-level resistance models. In models with high level resistance 
(>10 fold) there is less cross resistance between cisplatin and oxaliplatin, which may 
be a reason why oxaliplatin is thought to be active in cisplatin-resistant cancer. In 
clinical trials where oxaliplatin has been used as part of salvage therapy for patients 
who have failed cisplatin or carboplatin combination chemotherapy, there was a much 
lower response rate in patients with platinum-refractory or resistant cancers compared 
to platinum-sensitive cancers. This suggests that there may be cross-resistance 
between cisplatin and oxaliplatin in the clinic. Oxaliplatin as a single agent had a poor 
response rate in cisplatin refractory and resistant cancer. Oxaliplatin performed better 
in combination with other agents for the treatment of platinum resistant/refractory 
cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity 
and ability to be combined with other drugs rather than an underlying activity in 
cisplatin resistance. Oxaliplatin therefore should not be considered broadly active in 
cisplatin-resistant cancer.  
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Introduction 
 
The anti-proliferative properties of cisplatin were first observed in the 1960s. The first 
cancer patient received cisplatin in April 1971. Cisplatin quickly progressed through 
clinical trials becoming the first platinum compound approved for cancer therapy and 
has been used widely in cancer patients since 1978 
1
. Cisplatin is used in combination 
with other drugs to treat a variety of solid tumours and is one of the most successful 
chemotherapeutics used today. However, for those patients who do not respond to 
first line treatment or those who relapse with resistant disease, the prognosis is very 
poor 
2
. The past 30 years have seen extensive research into the mechanism of action 
of cisplatin, the development of new platinum drugs and research into the mechanisms 
of platinum drug resistance.  
 
Many other platinum drugs have been developed in an attempt to improve on 
cisplatin. Oxaliplatin is part of the ‘dach’ family of platinum compounds. This group 
of platinum compounds were first synthesised in 1972 by substituting the amine 
radicals of cisplatin with a ‘dach’ radial 
3
. The prototypes of this group showed 
promising anti-tumour activity but low solubility in water, limiting their potential use 
in the clinic. Modifications to improve water solubility were made and oxaliplatin was 
first synthesised in the late 1970s. Oxaliplatin demonstrated both aqueous solubility 
and anti-tumour activity 
4
. Oxaliplatin was shown to have activity against colon 
cancer in vitro 
4
 and is now used as a treatment for colon cancer in combination with 
5-fluorouracil 
5,6
. Oxaliplatin is a better tolerated chemotherapeutic than cisplatin, 
while both cause neurotoxicity, the toxicity of oxaliplatin is more rapidly reversible 
7,8
. 
 
Oxaliplatin has been widely regarded as potentially useful for the treatment of 
cisplatin-resistant cancer. Numerous clinical trials have been published using 
oxaliplatin as part of salvage therapy for cisplatin-resistant tumours. The pre-clinical 
evidence cited by these clinical studies for oxaliplatin’s activity in cisplatin-resistant 
cancer comes in general from studies of highly cisplatin-resistant cell lines with low-
level oxaliplatin resistance 
9,10
 or review articles summarising these findings and 
oxaliplatin in general 
11,12
. While highly resistant models are useful to understand the 
possible mechanisms of resistance, drug resistance in the clinical setting typically 
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occurs at lower levels of resistance 
13,14
 and may therefore involve different 
mechanisms of resistance.  
 
Other pre-clinical data cited as evidence of oxaliplatin’s activity in cisplatin resistant 
cancer is the differential activity of cisplatin and oxaliplatin in the National Cancer 
Institute’s panel of 60 cell lines 
4,15
. Oxaliplatin shows activity in colon carcinoma 
whereas cisplatin does not. Although these studies have been used to suggest a 
different profile of cross resistance between the two compounds, they only 
demonstrate that colon carcinoma cells are more sensitive to oxaliplatin and do not 
shed any light on the pattern of cross resistance between the two compounds in 
resistant cancers or other types of cancer.  
 
Oxaliplatin has been thought to have differing activity to cisplatin due to structural 
differences between the two molecules, yet both bind to and create adducts in GC rich 
areas of the DNA strand. There are many mechanisms by which cancer cells acquire 
resistance to platinum drugs, many of which have been characterised in resistant cell 
models. Mechanisms of platinum resistance common to both drugs include increased 
cellular glutathione leading to increased detoxification 
16,17
 or decreased accumulation 
of the drug within the cell 
18,17
 yet some models have neither of these mechanisms 
19
. 
The activity of oxaliplatin in some cisplatin-resistant cell lines is thought to be due to 
DNA repair or damage recognition processes that discriminate between cisplatin and 
oxaliplatin adducts. A loss of mismatch repair increases resistance to cisplatin 
adducts, but has no effect on oxaliplatin adducts in cell lines 
20
. However, this 
relationship remains to be confirmed in the clinic where studies show decreases in 
mismatch repair genes as prognostic of both increased 
21
 and decreased survival 
22
 in 
response to cisplatin based therapy. Mismatch repair genes have not as yet been 
examined in the clinic in response to oxaliplatin therapy. 
 
We undertook this systematic review to identify, describe and critique the clinical and 
pre-clinical evidence for the use of oxaliplatin in patients with “cisplatin-resistant” 
cancer. 
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Methods 
 
We conducted literature searches for pre-clinical and clinical studies using Medline. 
Review articles and articles not published in English were excluded. The reference 
lists in included papers were also searched for additional studies. Conference 
presentations and abstracts were not included. The literature searches were last 
updated in October 2006. 
 
Literature searches for pre-clinical studies 
 
Medline was searched for studies describing the cross-resistance between cisplatin 
and oxaliplatin in platinum-resistant cell lines using ‘cisplatin’, ‘oxaliplatin’, ‘cross 
resistance’, ‘cross resistant’, ‘resistant’, ‘resistance’ and ‘cell line’ as keywords. 
Resistance studies looking at a panel of cancer cell lines and the relative resistance 
between them were excluded, as these studies examine innate platinum resistance and 
not resistance developed from chemotherapy. Resistant cell lines resulting from 
transfection of cells were also excluded. Resistant cell lines developed using multiple 
drugs were also excluded, as this would introduce other factors to the cross resistance 
analysis between cisplatin and oxaliplatin. In some cases the same platinum-resistant 
cell line has been published with cisplatin and oxaliplatin cross resistance data in 
multiple publications. In this case the key publication has been listed in the table. 
 
Literature searches for clinical studies 
 
Medline was searched for all controlled clinical trials using oxaliplatin alone or in 
combination as treatment for patients who had previously received cisplatin or 
carboplatin based chemotherapy. ‘Oxaliplatin’, ‘cisplatin’ and ‘platinum’ were used 
as keywords and studies were limited to any clinical trial type. Studies using 
oxaliplatin as first line therapy were excluded. Studies where patients had no prior 
treatment with cisplatin or carboplatin were excluded. Studies including both cisplatin 
pre-treated and chemotherapy naïve patients were eligible as long as the results for 
platinum pre-treated patients were reported separately to allow data extraction.  
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Cisplatin and oxaliplatin resistance in pre-clinical studies 
 
The cellular models of platinum resistance can be divided into three groups. The first 
contain cell lines developed from patients before and after chemotherapy 
13,14
. The 
platinum sensitivity of these paired cell lines is usually determined by exposing them 
to a range of platinum concentrations and assessing cell viability with either an MTT 
or clonogenic assay. The IC50 (drug concentration causing 50% growth inhibition) for 
these paired cell lines can be used to determine the increase in resistance known as 
fold resistance by the following equation:- 
 
Fold Resistance = IC50 of Platinum Resistant Cell Line / IC50 of Parental Cell Line 
 
These studies have found that drug resistance in this clinical setting typically produces 
resistance of 2 to 3 fold 
13,14
.  
 
The second group contains those cell lines developed in a clinically relevant way with 
doses of 1-10 µg/ml as determined by pharmacokinetic studies 
23,24
. The scheduling of 
treatments may also be important since continuous exposure to drug is likely to 
produce higher levels of resistance as it does not mimic clinical therapy which is 
delivered in a pulsed manner with cycles of treatment. The third group contains the 
highly drug resistant models. Although these are valuable models for studying 
potential resistance mechanisms, they are less appropriate to study the activity of 
oxaliplatin at clinical levels of cisplatin resistance. 
 
The literature search for models of acquired platinum resistance which report cross 
resistance data for both cisplatin and oxaliplatin identified 25 platinum-resistant cell 
lines (Table 1). The majority of these cell lines are from the third group of cell models 
with high levels of resistance. The major mechanisms of resistance to platinum for 
each cell line in Table 1 is also listed. The resistance mechanism was not determined 
for some of the cell lines listed as most of these studies were aimed at showing a 
differential activity between cisplatin and oxaliplatin rather than determining the 
mechanisms of platinum resistance. 
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Table 1 -Cell Lines With Acquired Platinum Drug Resistance – Fold Resistance Data for Cisplatin and Oxaliplatin 
  Cell Line Cancer Treatment Dose and Strategy Cis 
Fold 
Ox 
Fold 
Resistance Mechanism Reference 
A431/Pt Cervical Continuous 0.1 µg/ml – 1 µg/ml 2.6 0.96 ↓Acc (Cis), ↓Adducts (Cis), ↓MSH2 
25,26
 
KB-3-1/KCP4 Epidermoid Continuous 7 µg/ml  51.3 94.5 ↑GSH  ↓Acc (Cis), ↑NER, ↓MSH6 
16
 
H12DDP Germ Cell Unknown dose Pulsed exposure over 49 weeks 8.0 2.0 ND 
9
 
P388/DDP Leukemia*  Single Dose 6-8 mg/kg  7.0 8.0 ND 
27
 
L1210/DDP Leukemia* Single Dose 6-8 mg/kg 40.0 1.0 ↑Replicative bypass of adducts (Cis) 
27,28
 
PC-9/CDDP NSCLC 15 months 0.5 µg/ml 18.3 5.1 ND 
10
 
PC-14/CDDP NSCLC 15 months 1.5 µg/ml 7.7 2.3 ND 
10
 
A2780-E(80) Ovarian Continuous 0.075 µg/ml -24 µg/ml 92.0 4.7 ↓Acc(Cis and Ox) 
4
 
KB CP(20) Ovarian Continuous 0.075 µg/ml - 6 µg/ml 78.0 2.7 ↓Acc(Cis and Ox) 
4 
A2780/CP Ovarian Unclear from previous literature 10.9 2.0 ↓Acc(Cis and Ox), ↑DNA Repair  
29
 
SKOV3-cis Ovarian Continuous stepwise to 20 µg/ml 4.0 5.3 ↓Acc(Cis), ↓P-gp 
18
 
A2780-cis Ovarian Continuous stepwise to 20 µg/ml 3.0 20.0 ↓Acc(Cis), ↑P-gp 
18 
H69CIS200 SCLC 8 4-day pulses 0.2 µg/ml 1.7 1.6 No change GSH or Acc 
19
 
Cisplatin 
(SCLC1)SR-2 SCLC 5 ng/ml 24 hour pulses then continuous 0.1 µg/ml  16.0 1.0 Increase in mutated MRP4 
30
 
HCT116/R1 Colon Continuous stepwise to 1.99 µg/ml 2.1 27.8 ND 
31
 
HCT116/R2 Colon Continuous stepwise to 4 µg/ml 2.9 68.4 ↓ pro-apoptotic Bax 
31
 
HCT116oxaliR Colon Pulsed 0.051 – 0.103 µg/ml  0.8 15.8 No change GSH or Pt Acc 
32
 
HT29oxaliR Colon Pulsed 0.131 – 0.262 µg/ml  0.6 13.3 No change GSH or Pt Acc 
32
 
A2780/C25 Ovarian Continuous 0.04 µg/ml – 9.93 µg/ml 5.1 8.4 ↓Acc (Cis and Ox), ↑GSH 
29,17
 
CH1oxaliR Ovarian Pulsed 0.079 – 0.159 µg/ml  3.9 3.0 No change GSH or Pt Acc 
32
 
A2780/C10 Ovarian  Continuous 0.04 µg/ml – 3.97 µg/ml 3.0 18.0 ↑GSH 
33,17
 
A2780oxaliR Ovarian Pulsed 0.030-0.060 µg/ml  1.2 3.7 No change GSH or Pt Acc 
32
 
Oxaliplatin 
H69OX400 SCLC 8 4-day pulses 0.4 µg/ml 1.8 1.8 No change GSH or Acc 
19
 
SKOV3-car Ovarian Continuous stepwise to 100 µg/ml 1.5 4.0 ↓Accumulation(Car), ↓P-gp 
18
 Carboplatin 
A2780-car Ovarian Continuous stepwise to 100 µg/ml 4.0 12.5 ↓Acc(Car), ↑P-gp 
18 
Acc – accumulation, Car – carboplatin, Cis – cisplatin, GSH – glutathione, ND – Not Determined, NER – nucleotide excision repair, NSCLC – non-small cell lung cancer, 
MRP4 – multidrug resistance associated protein 4, Ox – oxaliplatin, P-gp – P-glycoprotein, Pt – Platinum, Tax - taxol. * Murine cells. 
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For each cell line in Table 1 the fold oxaliplatin resistance was plotted against the fold 
cisplatin resistance, allowing an analysis of the pattern of cross resistance between the 
two compounds (Figure 1). The definition of cross resistance is a matter of debate in 
the literature. Some studies consider two drugs cross-resistant only if a similar level of 
resistance is observed. For the purposes of this review we have defined cross 
resistance between cisplatin and oxaliplatin as greater than or equal to 2-fold 
resistance to both drugs. This definition is therefore based on what would be clinically 
observed as cross resistance. 
 
Figure 1 shows that the majority of models of acquired platinum resistance are cross-
resistant to both cisplatin and oxaliplatin having at least 2-fold resistance to both 
drugs. The lower level resistant models, below 10-fold, tend to be cross-resistant to a 
similar level to both drugs. However, the higher level resistant models, above 10-fold 
indicated by grey shading, are highly resistant to their selecting drug and then exhibit 
a lower level of resistance to the other drug. This suggests that a common mechanism 
of low-level resistance to both cisplatin and oxaliplatin develops at clinical levels of 
drug treatment. Whereas the resistance mechanisms that develop at higher drug 
concentrations are likely to be more specific for the selecting drug. Figure 1 also 
shows that there is a limited number of clinically relevant models of cisplatin and 
oxaliplatin resistance, as most are well in excess of 2 to 3-fold. 
 
The cited evidence for the activity of oxaliplatin in cisplatin-resistant cancers comes 
from highly cisplatin-resistant cell models, where there is above 10-fold resistance to 
cisplatin and below 10-fold resistance to oxaliplatin 
4,29,10
 (indicated in grey in Figure 
1). However Figure 1 shows that the reverse is also true; where there is greater than 
10-fold resistance to oxaliplatin there is less than 10-fold resistance to cisplatin 
33,18
. 
This suggests that in high level drug resistance to either cisplatin or oxaliplatin there 
will be limited activity to the other drug. Furthermore, if the same degree of cross 
resistance occurred at high and low drug concentrations it is likely that more than one 
highly cross resistant cell line would have been found in the systematic review 
process.  The only highly cross resistant cell line found was the KB-3-1/KCP4 cells 
which were 51.3-fold resistant to cisplatin and 94.5-fold resistant to oxaliplatin 
16
. 
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Interestingly, two oxaliplatin-resistant colon carcinoma cell lines HCT116oxaliR and 
HT29oxaliR, shown in Figure 1, have become hypersensitive to cisplatin with a fold 
resistance for cisplatin of less than 1 
32
. This finding may relate to oxaliplatin’s unique 
activity in colon carcinoma 
4
; however, this hypersensitivity is not the case in all 
oxaliplatin resistant colon carcinomas found in the systematic review as HCT116/R1 
and HCT116/R2 show low-level cisplatin resistance 
31
. This suggests that cisplatin 
may have activity in oxaliplatin-resistant colon cancer. Further studies could be 
undertaken to examine this, although the clinical utility of cisplatin following 
oxaliplatin is likely to be low, due to cisplatin’s neurotoxicity 
34
. 
 
Oxaliplatin shows a lower level of cross resistance in the majority of highly cisplatin-
resistant cells (Figure 1). This does not represent an increase in activity in cisplatin 
resistance as this would be demonstrated by cell lines becoming hypersensitive to 
oxaliplatin which was not the case in the vast majority of cell lines found. Cisplatin 
and oxaliplatin-resistant cell lines are often hypersensitive to other non-platinum  
containing chemotherapeutics such as paclitaxel and taxotere 
19,35
. Paclitaxel has also 
shown promising results in the treatment of patients resistant to cisplatin 
36,37,38
. 
Therefore, paclitaxel and taxotere appear to have increased activity in platinum-
resistant cancer, although the mechanism of this activity is not fully understood. This 
is quite different to the pattern observed for the activity of oxaliplatin in cisplatin-
resistant cells. 
 
Oxaliplatin in the treatment of patients with cisplatin-resistant cancers 
 
Oxaliplatin has been used as a single agent and in combination with other 
chemotherapeutics for the treatment of cancers that are unresponsive to cisplatin or 
carboplatin based combination chemotherapy. Clinical platinum resistance is variably 
defined in the clinic and as such it is difficult to make comparisons of treatment 
activity between trials. The definition of platinum resistance is more critical in highly 
platinum sensitive diseases such as ovarian and testicular cancer. Many trialists define 
primary platinum resistance as disease progression during first-line treatment with a 
platinum containing regimen. However there is less agreement for secondary platinum 
resistance or potentially platinum sensitive patients, where it is common to use a 
platinum free interval, e.g. At least 6 months, to try to define patients as “potentially 
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sensitive”. Markman 
39
 describes a classification system to assist patient selection in 
second-line ovarian cancer studies. The relevance of this system to other cancers is 
however dependent on the innate platinum sensitivity of the underlying tumour type. 
 
Cisplatin combination chemotherapy is the cornerstone of treatment of ovarian and 
testicular carcinomas. Testicular carcinomas are exquisitely sensitive to cisplatin 
which cures > 80% of patients, however when resistance does occur the prognosis is 
usually poor 
40
. Similarly initial platinum responsiveness in ovarian cancer is high, but 
80% of patients will eventually relapse and be cisplatin resistant 
41
. 
 
Interpreting drug activity after platinum treatment even in these two highly platinum 
sensitive cancer types is further complicated by the common use of platinum in 
combination with other agents. Here, resistance to combination chemotherapy 
involves more than just resistance to platinum agents and the response to second line 
platinum containing regimens is influenced by the non-platinum agents used in both 
first and second line therapy. 
 
In our search of the literature for published controlled clinical trials describing the 
activity of oxaliplatin either as a single agent or in combination in the treatment of 
patients having previously received cisplatin based combination chemotherapy, we 
identified 24 studies. Using Markman’s criteria as a template, the patients within these 
studies were classified into five groups according to the following definitions. 
 
A) Platinum Refractory – Progression of disease or failure to achieve a partial 
response during last platinum based combination chemotherapy. 
B) Platinum Resistant – Progression of disease within 6 months after platinum based 
combination chemotherapy. 
C) Platinum Sensitive – Progression of disease greater than 6 months after platinum 
based combination chemotherapy. 
D) Non-Platinum Refractory – Patients who do not progress during platinum therapy 
but their individual time of disease progression after platinum treatment is not 
itemised in the study. These patients can therefore not be classified as platinum 
resistant (B) or platinum sensitive (C).  
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E) Unclassified – Patients who had been previously treated with platinum 
chemotherapy but where there was not enough information to classify in A, B, C or D. 
 
Tables 2 and 3 summarise the results on patients from clinical trials which have used 
oxaliplatin as a single agent and in combination respectively for the treatment of 
patients who have previously received cisplatin or carboplatin based chemotherapy.  
Patients from each study have been categorised as group A-E according to the above 
definitions. The pooled response rate (RR) of patients grouped by their platinum 
resistance status in 460 ovarian and 75 testicular cancer patients is presented in Figure 
2. Other cancer types found in the systematic review included, bladder, cervical, 
gastric, mesothelioma and NSCLC. However, only one study was found for each of 
these cancer types. 
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Table 2 – Single agent oxaliplatin in platinum pre-treated cancer 
Cancer Treatment Regimen Respondents Study Criteria for Platinum Resistance Reference 
Bladder  Oxaliplatin 130 mg/m
2
 every 
21 days 
B) 0/8 platinum resistant 
C) 1/10 platinum sensitive 
Resistance defined as progressive disease within 6 
months of a platinum regimen 
15
 
Cervical  Oxaliplatin 130 mg/m
2
 every 
21 days 
B) 0/15 platinum resistant  
C) 2/9 platinum sensitive 
Resistance defined as progressive disease within 6 
months of a platinum regimen 
42
 
Ovarian  Oxaliplatin 130 mg/m
2
 every 
21 days 
B)1/23 platinum resistant Resistance defined as progressive disease within 6 
months of a platinum regimen 
43
 
Ovarian Oxaliplatin 130 mg/m2 every 
21 days 
A) 1/18 platinum refractory  
C) 10/16 platinum sensitive 
D) 0/8 non-platinum refractory 
Resistance defined by Markman’s Criteria 41 
Ovarian Oxaliplatin 130 mg/m
2
 every 
21 days 
B) 2/32 platinum resistant 
C) 5/13 platinum sensitive 
Resistance defined as progressive disease within 6 
months of a platinum regimen 
44
 
Ovarian Oxaliplatin median dose of 
100 mg/m2 every 21 days 
A) 3/18 platinum refractory 
D) 6/13 non-platinum refractory 
Resistance defined by Markman’s Criteria  
45
 
Testicular  Oxaliplatin 130 mg/m2 every 
14 days or 60 mg/m
2
 every 7 
days for 3 cycles 
A) 0/7 platinum refractory 
B) 6/20 platinum resistant 
E) 0/5 unclassified 
Resistance defined as progressive disease within 4 
weeks of a platinum regimen or absolute defined as 
failure during therapy 
46 
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Table 3 - Oxaliplatin combination chemotherapy in platinum pre-treated cancer 
Cancer Treatment Regimen Respondents Study Criteria for Platinum 
Resistance/Sensitivity 
Reference 
Gastric Oxaliplatin 85mg/m
2
 and 5-FU 400 mg/m
2
 
Day 1 and Leucovorin 150 mg/m2 and 2.4-3 
g/m
2
 Day 3 every 14 days 
A) 6/20 platinum refractory 
D) 0/6 non-platinum refractory 
Resistance defined as progression during 
platinum therapy 
47
 
Mesothelioma Oxaliplatin 130 mg/m
2
 and Raltitrexed 3 
mg/m
2
 every 21 days 
E) 3/15 Unclassified Not defined by study 
48
 
Ovarian  Oxaliplatin 130 mg/m
2
 and Cisplatin 100 
mg/m
2
 every 21 days 
A) 3/13 Platinum refractory 
D) 7/12 non-platinum refractory 
Resistance defined by Markman’s Criteria 
49
 
Ovarian Taxol 135 mg/m
2 
Day 1, Oxaliplatin 100 
mg/m2 and  Cisplatin 75 mg/m2 Day 2, CGSF 
5µg/kg/d Days 6-13 every 21 days 
C) 6/7 platinum sensitive Sensitivity defined as > 12 months with 
progression free disease 
50
 
Ovarian Oxaliplatin 85 mg/m
2
, 5-FU 400 mg/m
2
 and 
Leucovorin 200 mg/m
2
 Day1 and 5-FU 600 
mg/m
2
 infusion Day 1 and 2 every 21 days  
B) 11/38 platinum resistant Resistance defined as progressive disease within 
6 months of a platinum regimen 
51
 
Ovarian Oxaliplatin 100-130 mg/m
2
 and Taxol 135-
175 mg/m2 every 21-28 days 
A) 6/18 platinum refractory 
D) 9/13 non-platinum refractory 
Resistance defined by Markman’s Criteria 
52
 
Ovarian Oxaliplatin 130 mg/m2 and Taxol 175 mg/m2 
every 21 days 
C) 79/98 platinum sensitive Sensitivity defined as 6 months with 
progression free disease 
53 
Ovarian Oxaliplatin 70 mg/m
2
 and Liposomal 
Doxorubicin 30-35 mg/m
2 
every 28 days 
B) 4/14 platinum resistant 
C) 18/27 platinum sensitive 
Resistance defined as progressive disease within 
6 months of a platinum regimen 
54
 
Ovarian Oxaliplatin 85 mg/m
2
 Day 1, 5-FU 370 mg/m
2
 
and Leucovorin 30 mg/m
2
 Days 1 and 8 – 
repeated every 14 days 
A) 0/2 platinum refractory 
B) 3/12 platinum resistant 
C) 3/6 platinum sensitive 
Resistance defined as progressive disease within 
6 months of a platinum regimen. Refractory 
defined as progression during platinum therapy 
55
 
Ovarian Oxaliplatin 85 mg/m2, Liposomal Doxorubicin 
30 mg/m
2
 and Cyclophosphamide 750 mg/m
2
 
every 21 days 
B) 10/27 platinum resistant 
C) 8/12 platinum sensitive 
Resistance defined as progressive disease within 
6 months of a platinum regimen. 
56 
Ovarian Oxaliplatin 85 mg/m
2
 Day 1and Gemcitabine 
1000 mg/m
2
 Day 1 and 8 every 21 days 
A) 0/3 platinum refractory 
B) 5/17 platinum resistant 
Resistance defined as progressive disease within 
6 months of a platinum regimen. Refractory 
defined as progression during platinum therapy 
57
 
Ovarian and 
NSCLC 
Oxaliplatin 70-100 mg/m2 and Gemcitabine 
800-1500 mg/m
2
 every 14 days 
B) 3/4 platinum resistant Resistance defined as progressive disease within 
6 months of a platinum regimen 
58 
Testicular  Oxaliplatin 85 mg/m
2
 Day 1and Gemcitabine B) 9/28 platinum resistant Resistance defined as progressive disease within 
59
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1000 mg/m2 Day 1 and 8 every 21 days 4 weeks of a platinum regimen 
Testicular  Oxaliplatin 85 mg/m2 Day 1and Gemcitabine 
1000 mg/m
2
 Day 1 and 8 every 21 days 
A) 2/9 platinum refractory 
B) 5/13 platinum resistant 
D) 9/13 non-platinum refractory 
Resistance defined as progressive disease within 
4 weeks of a platinum regimen or absolute 
defined as failure during therapy 
60 
Testicular  Oxaliplatin 85 mg/m
2
 Days 1 and 15, 
Irinotecan 80 mg/m
2
 Days 1, 8 and 15, 
prophylactic GCSF Days 3-6, 10-13 and 20-25 
every 28 days 
E) 7/18 unclassified Defined as failure to achieve a durable CR to a 
cisplatin-based regimen time to progression not 
itemised 
61
 
Testicular  Oxaliplatin 130 mg/m
2
 and Cisplatin 100 
mg/m
2
 every 21-28 days with up to four other 
drugs in combination 
A) 4/9 platinum refractory 
B) 0/1 platinum resistant 
C) 2/2 platinum sensitive 
Resistance defined as progressive disease during 
last platinum based regimen 
62
  
Testicular  Oxaliplatin 80 mg/m
2
, Taxol 70 mg/m
2
 and 
Gemcitabine 800 mg/m2 Days 1, 8 and 15 
every 28 days  
E) 1/7 unclassified Failure to respond to a platinum containing 
regimen time to progression not itemised 
63
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The pooled RR for single agent oxaliplatin in platinum refractory (n = 36, RR 11%) 
and platinum-resistant (n = 55, RR 5.5 %) ovarian cancer patients was similarly low 
(Figure 2i). However, the pooled RR was much higher for platinum-sensitive ovarian 
cancer patients (n = 29, RR = 51.7%). This observation suggests that in ovarian 
cancer, oxaliplatin as a single agent is not significantly active in cisplatin-resistant or 
refractory patients. Interpretation of the higher RR in the non-platinum refractory 
classification (n = 21, RR 28.6%) is confounded by the potential for misclassification 
of platinum-resistant versus platinum-sensitive patients due to lack of detail in the 
studies from which their data was extracted. However, the RR of the non-platinum 
refractory patients is higher than the platinum refractory patients. The RR of the non-
platinum refractory patients also falls between the RR for platinum-resistant and 
platinum-sensitive groups suggesting that there is a mixture of both groups of patients 
in this cohort.  
 
Figure 2i shows that oxaliplatin when used in combination achieves a higher response 
rate in all four groups of ovarian cancer patients than when used as a single agent. The 
pooled response rate of the platinum resistant (n = 108, RR = 30.55%) and refractory 
patients (n = 36, RR 25.0%) is similar and much lower than the platinum-sensitive 
patients (n=150, RR 76.0%). In the highly platinum-sensitive testicular cancers 
(Figure 2ii), the pooled RR for oxaliplatin combination chemotherapy was the same 
for platinum-refractory patients (n = 18, RR 33.3%), and platinum-resistant patients (n 
= 42, RR 33.3%). The response rate of platinum sensitive (n = 2, RR = 100%) and 
non-platinum refractory testicular cancers (n = 13, RR 69.2%) was higher but should 
be viewed with caution considering the low numbers of patients in these groups. In 
both ovarian and testicular cancer patients, the pooled RR was higher for platinum 
sensitive than platinum resistant or refractory patients. This suggests that oxaliplatin 
has less activity in cisplatin-resistant cancers. 
 
It is difficult to determine whether oxaliplatin alone or the combination of another 
drug with oxaliplatin is responsible for the response seen in cisplatin pre-treated 
patients. This question is unlikely to be resolved by further clinical trails as oxaliplatin 
used in combination therapy is associated with a greater response rate (Figure 2i).  
From the summary of cellular models of platinum resistance (Figure 1) and clinical 
trials of oxaliplatin as a single agent (Table 2), it appears that oxaliplatin alone lacks 
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sufficient activity to overcome cisplatin resistance. However, clinical trials 
demonstrating a response using oxaliplatin combination therapy in platinum-resistant 
patients often credit oxaliplatin’s lack of cross resistance for the success of treatment 
59,61
. The observed benefit from oxaliplatin combination regimens may well be due to 
the activity of the other agent or synergy between the two agents, rather than any 
innate ability for oxaliplatin to overcome cisplatin resistance. Furthermore, the more 
favourable toxicity profile of oxaliplatin lends itself for use in second-line 
combination regimens more readily than does cisplatin, and as such, cisplatin is not 
readily evaluated in this setting, even if it might be similarly active. 
 
There are many different mechanisms of platinum resistance as illustrated by the cell 
models in Table 1. Perhaps when the particular mechanism of cisplatin resistance in a 
relapsed patient can be diagnosed, such as the loss of mismatch repair where 
oxaliplatin shows differential activity to cisplatin 
20
, the most appropriate platinum 
agent for a patient could be selected. This review highlights that oxaliplatin is not 
active in all types of cisplatin resistance. The ability to stratify cisplatin-resistant 
patients as potentially oxaliplatin sensitive based on specific markers of resistance 
within the tumour, will lead to an improved response rate of oxaliplatin in a subgroup 
of patients. However, there is a need to examine the role of other non-platinum 
chemotherapeutics in the treatment of cisplatin-resistant cancers to combat the 
multiple forms of resistance. Future trials of oxaliplatin in cisplatin-resistant cancers 
should also integrate the study of markers of platinum resistance within the resistant 
tumour such as ERCC1, MSH2, MLH1, glutathione and platinum uptake to begin the 
shift to tailoring salvage chemotherapy to individual mechanisms of resistance. This 
would be similar to, and complement the pharmacogenomic approach examining 
germline polymorphisms in genes associated with platinum resistance with the 
response to firstline chemotherapy 
64
. 
 
Conclusions 
 
The conclusion that oxaliplatin is active in cisplatin-resistant cancer has in general 
been overstated in the literature. Oxaliplatin has some activity in highly cisplatin-
resistant cell lines however cisplatin has as much activity in highly-oxaliplatin 
resistant cell lines. The evidence from low-level platinum resistant cell lines and the 
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response of patients with cisplatin-resistant cancers suggest that there is cross-
resistance between cisplatin and oxaliplatin. Oxaliplatin is useful for the treatment of 
some cisplatin-resistant cancers when used in combination with other agents. The 
clinical benefit of oxaliplatin for the treatment of cisplatin-resistant cancer may lie 
with its more preferable toxicity profile, which allows successful combination with 
other agents rather than any greater activity in cisplatin-resistance.  
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Figure 1 – Cross resistance between cisplatin and oxaliplatin in cell models of 
acquired platinum resistance. The fold resistance of cisplatin and oxaliplatin of 
each resistant cell line compared to the parental cell line it was derived from is 
plotted (from Table 1). Cells developed with cisplatin (), oxaliplatin () and 
carboplatin () are indicated. The dotted line (….) at 1 indicates the fold resistance 
of the parental cell lines. The dashed line (---) at 2 indicates the level of clinical 
platinum resistance.
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Figure 2 – Response rate of platinum pre-treated patients to oxaliplatin divided by 
resistance status. The pooled results for i) ovarian cancer and ii) testicular cancer are divided 
up into four patient groups A) Platinum refractory B) Platinum resistant C) Platinum 
sensitive and D) Non-platinum Refractory. The open bars are patients who received 
oxaliplatin as single agent (), the closed bars are patients who received oxaliplatin 
combination chemotherapy (). The number of patients pooled in each group is indicated 
above each bar.
